For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Eisai Files Petition with US Court to Nudge DEA over Stalled Scheduling of Fycompa
August 23, 2013
- OrphanPacific to Launch Normosang, Second Ultra Orphan Drug, on Aug. 23
August 22, 2013
- Patent Cliff Hits Major Global Drug Makers, Weak Yen Weighs on Japan Sales
August 22, 2013
- Ajinomoto Obtains Approval for CCB Atelec Tab. 20
August 22, 2013
- Kowa Receives Approval for Livalo OD Tablets 4 mg in Japan
August 22, 2013
- G-CSF Biosimilars Now on the Market; a Three-way Battle Begins
August 21, 2013
- Biosimilars to a Number of Major Drugs Including Remicade and Avastin Now in Development or in Preparation for Development
August 21, 2013
- Zeria Obtains Exclusive Rights in Japan for Iron Deficiency Treatment Ferinject from Vifor Pharma of Switzerland
August 21, 2013
- Increasing Awareness of Biosimilars to Establish Them as a New Category; Companies Forming Alliances to Build Development and Marketing System
August 21, 2013
- ASKA to Roll Out Generics of Takeda Product for 1st Time
August 20, 2013
- M3 to Team Up with Yahoo Japan on Healthcare Advertising Business
August 20, 2013
- Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
- BMKK, AZ Join the Fray in the Domestic Diabetes Market; Will Build Their Foundation on Byetta, Bydureon
August 20, 2013
- Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
- A Record 32 Officials at Drug-related Companies Were Paid Over 100 Million Yen in FY2012; Hiroshi Mitsuhara Was Top-paid Official of a Pharmacy Chain for the 4th Year in a Row
August 16, 2013
- Swiss OKs Schizophrenia Treatment Lurasidone: DSP, Takeda
August 15, 2013
- ViiV Healthcare Wins US Regulatory Approval for Anti-HIV Drug Dolutegravir
August 15, 2013
- Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles
August 15, 2013
- Eisai Paid a Total of 18.7 Billion Yen to Doctors and Medical Institutions, 1.1 Billion Yen for Research Grants
August 14, 2013
- Sitagliptin Filed for Combination Therapy with Glinides: MSD, Ono
August 14, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…